Latest news with #IART
Yahoo
6 days ago
- Business
- Yahoo
1 of Wall Street's Favorite Stock Worth Investigating and 2 to Be Wary Of
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it's worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover. At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here is one stock likely to meet or exceed Wall Street's lofty expectations and two where analysts may be overlooking some important risks. Consensus Price Target: $17.14 (22.2% implied return) With over 2,400 hours of local news produced weekly and 640 broadcast channels reaching millions of American homes, Sinclair (NASDAQ:SBGI) operates a network of 185 local television stations across 86 U.S. markets, producing news programming and distributing content from major networks. Why Should You Sell SBGI? Sales tumbled by 7.2% annually over the last five years, showing market trends are working against its favor during this cycle Estimated sales decline of 9.2% for the next 12 months implies a challenging demand environment Incremental sales over the last two years were much less profitable as its earnings per share fell by 25.1% annually while its revenue grew At $14.03 per share, Sinclair trades at 2.3x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than SBGI. Consensus Price Target: $16.13 (27.2% implied return) Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Why Do We Pass on IART? Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Earnings per share fell by 1.2% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable Free cash flow margin shrank by 17.1 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive Integra LifeSciences's stock price of $12.68 implies a valuation ratio of 4.9x forward P/E. To fully understand why you should be careful with IART, check out our full research report (it's free). Consensus Price Target: $129.31 (71.2% implied return) Pioneering the "Find, Fight and Follow" approach to disease management, Lantheus Holdings (NASDAQGM:LNTH) develops and commercializes radiopharmaceuticals and other imaging agents that help healthcare professionals detect, diagnose, and treat diseases. Why Do We Like LNTH? Impressive 34.3% annual revenue growth over the last five years indicates it's winning market share this cycle Free cash flow margin increased by 29.5 percentage points over the last five years, giving the company more capital to invest or return to shareholders Improving returns on capital reflect management's ability to monetize investments Lantheus is trading at $75.54 per share, or 10.5x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free.
Washington Post
05-05-2025
- Business
- Washington Post
Integra: Q1 Earnings Snapshot
PRINCETON, N.J. — PRINCETON, N.J. — Integra LifeSciences Holdings Corp. (IART) on Monday reported a loss of $25.3 million in its first quarter. The Princeton, New Jersey-based company said it had a loss of 33 cents per share. Earnings, adjusted for one-time gains and costs, came to 41 cents per share.
Yahoo
05-05-2025
- Business
- Yahoo
Integra: Q1 Earnings Snapshot
PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Integra LifeSciences Holdings Corp. (IART) on Monday reported a loss of $25.3 million in its first quarter. The Princeton, New Jersey-based company said it had a loss of 33 cents per share. Earnings, adjusted for one-time gains and costs, came to 41 cents per share. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 43 cents per share. The medical device maker posted revenue of $382.7 million in the period, exceeding Street forecasts. Six analysts surveyed by Zacks expected $382.2 million. For the current quarter ending in June, Integra expects its per-share earnings to range from 40 cents to 45 cents. The company said it expects revenue in the range of $390 million to $400 million for the fiscal second quarter. Integra expects full-year earnings in the range of $2.19 to $2.29 per share, with revenue ranging from $1.65 billion to $1.72 billion. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on IART at Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
1 Small-Cap Stock with Solid Fundamentals and 2 to Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here is one small-cap stock that could be the next 100 bagger and two that could be down big. Market Cap: $483.1 million Founded by explorer Sven-Olof Lindblad in 1979, Lindblad Expeditions (NASDAQ:LIND) offers cruising experiences to remote destinations in partnership with National Geographic. Why Is LIND Risky? Annual revenue growth of 13.4% over the last five years was below our standards for the consumer discretionary sector Incremental sales over the last five years were much less profitable as its earnings per share fell by 73% annually while its revenue grew Projected 3.8 percentage point decline in its free cash flow margin next year reflects the company's plans to increase its investments to defend its market position Lindblad Expeditions's stock price of $8.72 implies a valuation ratio of 4.3x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why LIND doesn't pass our bar. Market Cap: $1.29 billion Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Why Are We Out on IART? Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 1.4% annually Free cash flow margin dropped by 10.5 percentage points over the last five years, implying the company became more capital intensive as competition picked up Integra LifeSciences is trading at $16.69 per share, or 6.7x forward price-to-earnings. To fully understand why you should be careful with IART, check out our full research report (it's free). Market Cap: $878.3 million Creating the first packaged tracing systems, Thermon (NYSE:THR) is a leading provider of engineered industrial process heating solutions for process industries. Why Are We Positive On THR? Offerings are difficult to replicate at scale and lead to a top-tier gross margin of 42.3% Operating margin improvement of 9.5 percentage points over the last five years demonstrates its ability to scale efficiently Free cash flow margin expanded by 3.2 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends At $26.07 per share, Thermon trades at 13.3x forward price-to-earnings. Is now a good time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free.
Yahoo
01-04-2025
- Business
- Yahoo
Argus upgrades Integra to Buy, says well-positioned for a turnaround
Argus analyst David Toung upgraded Integra LifeSciences (IART) to Buy from Hold with a $28 price target The firm sees the company as well-positioned for a turnaround, and with supply issues for Integra Skin products resolved, the company now expects sequentially stronger top and bottom-line growth as 2025 progresses. Argus also expects that under the leadership of new CEO Mojdeh Poul, the company will improve operations and sales execution in order tot meet demand for its reconstructive and neurosurgery products. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on IART: Disclaimer & DisclosureReport an Issue Integra LifeSciences upgraded to Buy from Hold at Argus Integra LifeSciences Reports Mixed Earnings Amid Challenges Sell Rating on Integra Lifesciences Amidst Uncertain Growth and Leadership Transition Integra Lifesciences Faces Supply Chain Challenges and Conservative Outlook, Leading to Sell Rating Optimistic Growth Outlook for Integra LifeSciences Amidst Transitional Phase and Strategic Initiatives Sign in to access your portfolio
